The key role of T cells in Parkinson's disease pathogenesis and therapy

Jill K. Baird, Dennis Bourdette, Charles K. Meshul, Joseph Quinn

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This review focuses on the role of T lymphocytes in the pathogenesis of Parkinson's disease and highlights evidence for modulation of the T cell response as an effective neuroprotective strategy. In preclinical models of Parkinson's disease, modulation of the T cell response results in neuroprotection. Peripheral markers of T cell response show changes in Parkinson's patients relative to controls that have potential application as diagnostic and therapeutic biomarkers. The article also discusses the important immunomodulatory effects of dopamine which may confound study of T cells in patients on dopaminergic therapies, and highlights glatiramer acetate, an FDA-approved therapy for multiple sclerosis that works through modulating the T cell response, as a promising target for translation.

Original languageEnglish (US)
JournalParkinsonism and Related Disorders
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Parkinson Disease
T-Lymphocytes
Therapeutics
Multiple Sclerosis
Dopamine
Biomarkers

Keywords

  • Biomarkers
  • Dopamine
  • Glatiramer acetate
  • Immunomodulation
  • Neuroinflammation
  • Neuroprotection
  • Parkinson's disease
  • Pathogenesis
  • T cells
  • T lymphocytes

ASJC Scopus subject areas

  • Neurology
  • Geriatrics and Gerontology
  • Clinical Neurology

Cite this

The key role of T cells in Parkinson's disease pathogenesis and therapy. / Baird, Jill K.; Bourdette, Dennis; Meshul, Charles K.; Quinn, Joseph.

In: Parkinsonism and Related Disorders, 01.01.2018.

Research output: Contribution to journalArticle

@article{eb66d3dc847c4c0991d9f579cb9e7e92,
title = "The key role of T cells in Parkinson's disease pathogenesis and therapy",
abstract = "This review focuses on the role of T lymphocytes in the pathogenesis of Parkinson's disease and highlights evidence for modulation of the T cell response as an effective neuroprotective strategy. In preclinical models of Parkinson's disease, modulation of the T cell response results in neuroprotection. Peripheral markers of T cell response show changes in Parkinson's patients relative to controls that have potential application as diagnostic and therapeutic biomarkers. The article also discusses the important immunomodulatory effects of dopamine which may confound study of T cells in patients on dopaminergic therapies, and highlights glatiramer acetate, an FDA-approved therapy for multiple sclerosis that works through modulating the T cell response, as a promising target for translation.",
keywords = "Biomarkers, Dopamine, Glatiramer acetate, Immunomodulation, Neuroinflammation, Neuroprotection, Parkinson's disease, Pathogenesis, T cells, T lymphocytes",
author = "Baird, {Jill K.} and Dennis Bourdette and Meshul, {Charles K.} and Joseph Quinn",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.parkreldis.2018.10.029",
language = "English (US)",
journal = "Parkinsonism and Related Disorders",
issn = "1353-8020",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - The key role of T cells in Parkinson's disease pathogenesis and therapy

AU - Baird, Jill K.

AU - Bourdette, Dennis

AU - Meshul, Charles K.

AU - Quinn, Joseph

PY - 2018/1/1

Y1 - 2018/1/1

N2 - This review focuses on the role of T lymphocytes in the pathogenesis of Parkinson's disease and highlights evidence for modulation of the T cell response as an effective neuroprotective strategy. In preclinical models of Parkinson's disease, modulation of the T cell response results in neuroprotection. Peripheral markers of T cell response show changes in Parkinson's patients relative to controls that have potential application as diagnostic and therapeutic biomarkers. The article also discusses the important immunomodulatory effects of dopamine which may confound study of T cells in patients on dopaminergic therapies, and highlights glatiramer acetate, an FDA-approved therapy for multiple sclerosis that works through modulating the T cell response, as a promising target for translation.

AB - This review focuses on the role of T lymphocytes in the pathogenesis of Parkinson's disease and highlights evidence for modulation of the T cell response as an effective neuroprotective strategy. In preclinical models of Parkinson's disease, modulation of the T cell response results in neuroprotection. Peripheral markers of T cell response show changes in Parkinson's patients relative to controls that have potential application as diagnostic and therapeutic biomarkers. The article also discusses the important immunomodulatory effects of dopamine which may confound study of T cells in patients on dopaminergic therapies, and highlights glatiramer acetate, an FDA-approved therapy for multiple sclerosis that works through modulating the T cell response, as a promising target for translation.

KW - Biomarkers

KW - Dopamine

KW - Glatiramer acetate

KW - Immunomodulation

KW - Neuroinflammation

KW - Neuroprotection

KW - Parkinson's disease

KW - Pathogenesis

KW - T cells

KW - T lymphocytes

UR - http://www.scopus.com/inward/record.url?scp=85055953816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055953816&partnerID=8YFLogxK

U2 - 10.1016/j.parkreldis.2018.10.029

DO - 10.1016/j.parkreldis.2018.10.029

M3 - Article

JO - Parkinsonism and Related Disorders

JF - Parkinsonism and Related Disorders

SN - 1353-8020

ER -